Citizens raised the firm’s price target on Abivax (ABVX) to $131 from $114 and keeps an Outperform rating on the shares. Abivax reported Q3 results and business updates, highlighting positive Phase 3 ulcerative colitis data announced in August that continue to support a potentially practice-changing profile, the analyst tells investors in a research note. The company expects Phase 3 maintenance results in 2Q26 and Phase 2b Crohn’s disease data in the second half of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax SA Reports Increased Losses in Q3 2025 Amid Rising R&D Costs
- Options Volatility and Implied Earnings Moves Today, December 15, 2025
- Options Volatility and Implied Earnings Moves This Week, December 15 – December 19, 2025
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 14
- ABVX Earnings Report this Week: Is It a Buy, Ahead of Earnings?